immunovant sciences holdings limited
immunovant sciences holdings limited Company Information
Company Number
11460737
Next Accounts
Dec 2025
Industry
Activities of other holding companies (not including agricultural, production, construction, distribution and financial services holding companies) n.e.c.
Shareholders
immunovant sciences ltd
Group Structure
View All
Contact
Registered Address
7th floor 50 broadway, london, SW1H 0DB
Website
-immunovant sciences holdings limited Estimated Valuation
Pomanda estimates the enterprise value of IMMUNOVANT SCIENCES HOLDINGS LIMITED at £0 based on a Turnover of £0 and 1.14x industry multiple (adjusted for size and gross margin).
immunovant sciences holdings limited Estimated Valuation
Pomanda estimates the enterprise value of IMMUNOVANT SCIENCES HOLDINGS LIMITED at £0 based on an EBITDA of £-25.4k and a 4.41x industry multiple (adjusted for size and gross margin).
immunovant sciences holdings limited Estimated Valuation
Pomanda estimates the enterprise value of IMMUNOVANT SCIENCES HOLDINGS LIMITED at £0 based on Net Assets of £-20.5k and 1.31x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Immunovant Sciences Holdings Limited Overview
Immunovant Sciences Holdings Limited is a live company located in london, SW1H 0DB with a Companies House number of 11460737. It operates in the activities of other holding companies n.e.c. sector, SIC Code 64209. Founded in July 2018, it's largest shareholder is immunovant sciences ltd with a 100% stake. Immunovant Sciences Holdings Limited is a young, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Immunovant Sciences Holdings Limited Health Check
There is insufficient data available to calculate a health check for Immunovant Sciences Holdings Limited. Company Health Check FAQs
0 Strong
0 Regular
2 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Immunovant Sciences Holdings Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Immunovant Sciences Holdings Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Immunovant Sciences Holdings Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Immunovant Sciences Holdings Limited
- - Industry AVG
Employees
with 2 employees, this is below the industry average (105)
- - Immunovant Sciences Holdings Limited
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- - Immunovant Sciences Holdings Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- - Immunovant Sciences Holdings Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Immunovant Sciences Holdings Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Immunovant Sciences Holdings Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Immunovant Sciences Holdings Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Immunovant Sciences Holdings Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 209.7%, this is a higher level of debt than the average (68.2%)
- - Immunovant Sciences Holdings Limited
- - Industry AVG
IMMUNOVANT SCIENCES HOLDINGS LIMITED financials
Immunovant Sciences Holdings Limited's latest turnover from March 2024 is 0 and the company has net assets of -£20.5 thousand. According to their latest financial statements, Immunovant Sciences Holdings Limited has 2 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | |
|---|---|---|---|---|---|---|
| Turnover | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income Or Grants | ||||||
| Cost Of Sales | ||||||
| Gross Profit | ||||||
| Admin Expenses | ||||||
| Operating Profit | -25,357 | -25,577 | -21,419 | -34,392 | -20,927 | -14,641 |
| Interest Payable | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Receivable | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-Tax Profit | -25,357 | -25,577 | -21,419 | -34,392 | -20,927 | -14,641 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | -25,357 | -25,577 | -21,419 | -34,392 | -20,927 | -14,641 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | -25,357 | -25,577 | -21,419 | -34,392 | -20,927 | -14,641 |
| Employee Costs | 0 | 0 | 0 | 0 | 0 | 0 |
| Number Of Employees | 2 | 2 | 2 | 2 | 2 | |
| EBITDA* | -25,357 | -25,577 | -21,419 | -34,392 | -20,927 | -14,641 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | |
|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 16,288 | 16,288 | 16,360 | 17,155 | 15,662 | 15,183 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 16,288 | 16,288 | 16,360 | 17,155 | 15,662 | 15,183 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 |
| Group Debtors | 0 | 5,986 | 31,190 | 59,966 | 80,376 | 70,099 |
| Misc Debtors | 2,384 | 2,099 | 2,243 | 2,315 | 0 | 0 |
| Cash | 0 | 0 | 0 | 0 | 0 | 0 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 2,385 | 8,086 | 33,434 | 62,282 | 80,377 | 70,100 |
| total assets | 18,672 | 24,374 | 49,794 | 79,436 | 96,039 | 85,282 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 19,559 | 8 | 8 | 8 | 8 | 7 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 19,590 | 19,486 | 19,194 | 24,891 | 14,841 | 8,289 |
| total current liabilities | 39,150 | 19,495 | 19,202 | 24,900 | 14,849 | 8,297 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 39,150 | 19,495 | 19,202 | 24,900 | 14,849 | 8,297 |
| net assets | -20,478 | 4,879 | 30,591 | 54,536 | 81,190 | 76,986 |
| total shareholders funds | -20,478 | 4,879 | 30,591 | 54,536 | 81,190 | 76,986 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Operating Profit | -25,357 | -25,577 | -21,419 | -34,392 | -20,927 | -14,641 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | -5,702 | -25,347 | -28,848 | -18,095 | 10,277 | 70,099 |
| Creditors | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 104 | 292 | -5,697 | 10,050 | 6,552 | 8,289 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | -19,551 | 62 | 1,732 | -6,247 | -24,652 | -76,451 |
| Investing Activities | ||||||
| capital expenditure | ||||||
| Change in Investments | 0 | -72 | -795 | 1,493 | 479 | 15,183 |
| cash flow from investments | ||||||
| Financing Activities | ||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 19,551 | 0 | 0 | 1 | 0 | 7 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||
| interest | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from financing | 19,551 | -135 | -2,526 | 7,740 | 25,131 | 91,634 |
| cash and cash equivalents | ||||||
| cash | 0 | 0 | 0 | 0 | 0 | 0 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 0 | 0 | 0 | 0 | 0 | 0 |
immunovant sciences holdings limited Credit Report and Business Information
Immunovant Sciences Holdings Limited Competitor Analysis
Perform a competitor analysis for immunovant sciences holdings limited by selecting its closest rivals, whether from the FINANCIAL AND INSURANCE ACTIVITIES sector, other young companies, companies in SW1H area or any other competitors across 12 key performance metrics.
immunovant sciences holdings limited Ownership
IMMUNOVANT SCIENCES HOLDINGS LIMITED group structure
Immunovant Sciences Holdings Limited has no subsidiary companies.
Ultimate parent company
IMMUNOVANT SCIENCES LTD
#0107736
1 parent
IMMUNOVANT SCIENCES HOLDINGS LIMITED
11460737
immunovant sciences holdings limited directors
Immunovant Sciences Holdings Limited currently has 2 directors. The longest serving directors include Mr Lee Moore (Jul 2018) and Mrs Caterina Juer (Apr 2023).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Lee Moore | England | 44 years | Jul 2018 | - | Director |
| Mrs Caterina Juer | United Kingdom | 41 years | Apr 2023 | - | Director |
P&L
March 2024turnover
0
0%
operating profit
-25.4k
-1%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
-20.5k
-5.2%
total assets
18.7k
-0.23%
cash
0
0%
net assets
Total assets minus all liabilities
immunovant sciences holdings limited company details
company number
11460737
Type
Private limited with Share Capital
industry
64209 - Activities of other holding companies (not including agricultural, production, construction, distribution and financial services holding companies) n.e.c.
incorporation date
July 2018
age
7
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
March 2024
previous names
N/A
accountant
-
auditor
EISNERAMPER AUDIT LIMITED
address
7th floor 50 broadway, london, SW1H 0DB
Bank
-
Legal Advisor
-
immunovant sciences holdings limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to immunovant sciences holdings limited.
immunovant sciences holdings limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for IMMUNOVANT SCIENCES HOLDINGS LIMITED. This can take several minutes, an email will notify you when this has completed.
immunovant sciences holdings limited Companies House Filings - See Documents
| date | description | view/download |
|---|
